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Identification, characterization, and application of a recombinant
antigen for the serological investigation of feline hemotropic
Mycoplasma infections
Abstract
In felids, three hemotropic mycoplasma species (hemoplasmas) have been described: Mycoplasma
haemofelis, "Candidatus Mycoplasma haemominutum," and "Candidatus Mycoplasma turicensis." In
particular, M. haemofelis may cause severe, potentially life-threatening hemolytic anemia. No routine
serological assays for feline hemoplasma infections are available. Thus, the goal of our project was to
identify and characterize an M. haemofelis antigen (DnaK) that subsequently could be applied as a
recombinant antigen in a serological assay. The gene sequence of this protein was determined using
consensus primers and blood samples from two naturally M. haemofelis-infected Swiss pet cats, an
experimentally M. haemofelis-infected specific-pathogen-free cat, and a naturally M.
haemofelis-infected Iberian lynx (Lynx pardinus). The M. haemofelis DnaK gene sequence showed the
highest identity to an analogous protein of a porcine hemoplasma (72%). M. haemofelis DnaK was
expressed recombinantly in an Escherichia coli DnaK knockout strain and purified using Ni affinity,
size-exclusion, and anion-exchange chromatography. It then was biochemically and functionally
characterized and showed characteristics typical for DnaKs (secondary structure profile, thermal
denaturation, ATPase activity, and DnaK complementation). Moreover, its immunogenicity was
assessed using serum samples from experimentally hemoplasma-infected cats. In Western blotting or
enzyme-linked immunosorbent assays, it was recognized by sera from cats infected with M. haemofelis,
"Ca. Mycoplasma haemominutum," and "Ca. Mycoplasma turicensis," respectively, but not from
uninfected cats. This is the first description of a full-length purified recombinant feline hemoplasma
antigen that can readily be applied in future pathogenesis studies and may have potential for application
in a diagnostic serological test.
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In felids, three hemotropic mycoplasma species (hemoplasmas) have been described: Mycoplasma haemofelis,
“Candidatus Mycoplasma haemominutum,” and “Candidatus Mycoplasma turicensis.” In particular, M. hae-
mofelis may cause severe, potentially life-threatening hemolytic anemia. No routine serological assays for feline
hemoplasma infections are available. Thus, the goal of our project was to identify and characterize an M.
haemofelis antigen (DnaK) that subsequently could be applied as a recombinant antigen in a serological assay.
The gene sequence of this protein was determined using consensus primers and blood samples from two
naturally M. haemofelis-infected Swiss pet cats, an experimentally M. haemofelis-infected specific-pathogen-free
cat, and a naturally M. haemofelis-infected Iberian lynx (Lynx pardinus). The M. haemofelis DnaK gene sequence
showed the highest identity to an analogous protein of a porcine hemoplasma (72%). M. haemofelis DnaK was
expressed recombinantly in an Escherichia coli DnaK knockout strain and purified using Ni affinity, size-
exclusion, and anion-exchange chromatography. It then was biochemically and functionally characterized and
showed characteristics typical for DnaKs (secondary structure profile, thermal denaturation, ATPase activity,
and DnaK complementation). Moreover, its immunogenicity was assessed using serum samples from experi-
mentally hemoplasma-infected cats. In Western blotting or enzyme-linked immunosorbent assays, it was
recognized by sera from cats infected with M. haemofelis, “Ca. Mycoplasma haemominutum,” and “Ca.
Mycoplasma turicensis,” respectively, but not from uninfected cats. This is the first description of a full-length
purified recombinant feline hemoplasma antigen that can readily be applied in future pathogenesis studies and
may have potential for application in a diagnostic serological test.
Hemotropic mycoplasmas (hemoplasmas) are small (0.3 to
0.8 m) epierythrocytic bacteria, which previously have been
known as Haemobartonella and Eperythrozoon species. In fe-
lids, Mycoplasma haemofelis, “Candidatus Mycoplasma haemo-
minutum,” and “Candidatus Mycoplasma turicensis” have
been described (5, 6, 19, 36). They vary in their pathogenicity,
responsiveness to antimicrobial drugs, and probably in their
ability to form a carrier state (5, 26, 36). M. haemofelis in
particular may cause severe, potentially life-threatening hemo-
lytic anemia (5).
Real-time PCR assays are the tools of choice for diagnosing
and differentiating feline hemoplasma infections (29, 36).
However, they may not detect all hemoplasma infections, e.g.,
due to fluctuating M. haemofelis bacteremia (29), reduced bac-
terial blood loads after antibiotic treatment (5), or chronic
carrier status of infected animals with undetectable numbers of
circulating hemoplasmas (28). To overcome the resulting di-
agnostic gap and to further characterize the course and patho-
genesis of feline hemoplasma infections, a diagnostic assay
based on serum antibody detection would be desirable.
To date, no routine serological assays for the diagnosis of
feline hemoplasma infections are available. The development
of such assays has been significantly hampered by the fact that
hemoplasmas cannot be cultured in vitro, and therefore anti-
gens have had to be produced by the experimental infection of
cats with hemoplasmas. Experimental serological assays have
been described using hemoplasma antigen either on blood
smears (5) or purified from large volumes of blood (1) from
infected cats. Western blot analyses of Haemobartonella felis
antigen preparations resulted in the identification of five anti-
gens recognized by sera from experimentally H. felis-infected
cats (1). A recent study identified M. haemofelis antigens in
crude antigen preparations from erythrocytes collected from
an experimentally infected cat (21). Those antigens reacted
with plasma antibodies of cats collected at different time points
after experimental infection when applied in Western blot
analyses. The first recombinant hemoplasma antigen, Myco-
plasma suis HspA1, was developed during a study of experi-
mentally M. suis-infected pigs for application in Western blot-
ting and enzyme-linked immunosorbent assays (ELISAs) (10).
This antigen belongs to the heat shock protein 70 (HSP70)
family. It was found to be DnaK-like and present on the sur-
face of M. suis (10). DnaKs are molecular chaperones consist-
ing of an N-terminal nucleotide-binding domain (ATPase ac-
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tivity) that generates the energy necessary to refold misfolded
proteins in cell stress situations (9). Misfolded proteins bind to
the C-terminal substrate-binding domain of DnaKs. Most re-
cently, we developed a recombinant feline hemoplasma anti-
gen to demonstrate the seroconversion of experimentally “Ca.
Mycoplasma turicensis”-infected cats in preliminary Western
blot analyses (18). The antigen described was a truncated M.
haemofelis DnaK form recombinantly expressed in E. coli that
was only partially purified, leading to large interbatch varia-
tions with regard to quality and purity. The described assay did
not allow for the quantification of antibody levels.
The aim of this study was to identify the complete DnaK
gene of M. haemofelis, to recombinantly produce, highly purify,
and characterize the antigen, and to apply it in an ELISA as a
serological tool for the detection and quantification of the
humoral immune response during experimental feline hemo-
plasma infection.
MATERIALS AND METHODS
Animals, experimental hemoplasma infections, and samples. All animals from
which samples have been used during this study are listed in Table 1. For
sequencing purposes, samples from the following six hemoplasma-infected felids
were used: the experimentally M. haemofelis-infected specific-pathogen-free
(SPF) cat QLA5 (Liberty Research, Waverly, NY), the naturally M. haemofelis-
infected Swiss domestic pet cats 1008 and 7415 (35), the free-living Iberian lynxes
(Lynx pardinus) Dalia and Cicuta, which were naturally infected with M. hae-
mofelis and “Ca. Mycoplasma haemominutum,” respectively (16), and the ex-
perimentally “Ca. Mycoplasma turicensis”-infected SPF cat Y (18). For the
ELISA, pre- and postinfection samples from a total of 20 SPF cats were used,
including the M. haemofelis-infected cat QLA5, 8 “Ca. Mycoplasma haemominu-
tum”-infected cats, such as cat 09NFR2, and 11 “Ca. Mycoplasma turicensis”-
infected cats, such as cat Y (Table 1).
The experimental infections of the “Ca. Mycoplasma haemominutum”- and
“Ca. Mycoplasma turicensis”-infected cats have been described earlier (7, 18).
For experimental M. haemofelis infection, the SPF cat QLA5 was inoculated
intraperitoneally at the age of 2.7 years with 2 ml of dimethylsulfoxide (DMSO)-
preserved (20%, vol/vol) M. haemofelis-positive blood from the experimentally
infected cat HF3 (31). The inoculum contained 109 M. haemofelis copies/ml, as
determined by TaqMan real-time PCR (35), and had been stored at 80°C until
use. All SPF cats were kept in groups (QLA5 was kept together with a female
neutered SPF companion cat) and examined clinically prior to the study, and
their SPF status was verified as described previously (18).
After hemoplasma inoculation, EDTA-anticoagulated whole-blood samples
were collected regularly, hemograms were generated using a Cell-Dyn 3500
(Abbott; Baar/Switzerland), and the quantification of hemoplasma blood loads
was performed by TaqMan real-time PCR (35). Serum or plasma samples were
collected for serological analyses (see below). Anemia was defined as a hemato-
crit value of less than 33% (equal to a 5% quantile of the reference range
determined in our laboratory using identical methods and blood samples from 58
clinically healthy cats). EDTA-anticoagulated blood samples collected from cat
QLA5 (4.4 108 copies/ml blood), cat 1008 (2.8 108 copies/ml blood), cat 7415
(8.0  106 copies/ml blood), and from lynx Dalia (6.6  104 copies/ml blood) 10
days postinfection (dpi) were used for M. haemofelis DnaK gene amplification
and sequencing. DNA from 1 ml of blood of cat QLA5 was extracted manually
using the QIAmp DNA blood mini kit (Qiagen, Hombrechtikon, Switzerland).
Total nucleic acids from cats 1008, 7415, and lynx Dalia were extracted from 200
l of blood using the MagNa pure LC total nucleic acid isolation kit I (Roche
Diagnostics, Reinach, Switzerland).
Determination of M. haemofelis DnaK gene sequence and phylogenetic anal-
ysis. Based upon the sequence information of M. haemofelis DnaK gene frag-
ments AY150993 (303 bp) and FJ463263 (899 bp) and of all other mycoplasma
DnaK gene sequences available from the GenBank database until June 2009,
several consensus primer pairs were designed manually and tested for the am-
plification of the potential M. haemofelis DnaK gene. Using the primer pairs
F1-35Mp/R934-956Mhf and F600-623Var/R1746-1768Ms (Table 2), the M. hae-
mofelis DnaK gene was amplified as two overlapping fragments of 976 and 1,307
bp, respectively. The following thermal cycling conditions were applied: initial
denaturation at 98°C for 180 s, 35 cycles of 98°C for 10 s, 60 (976 bp) or 63°C
TABLE 1. Animals from which samples have been used for sequencing and serology
Identitya Species, SPF status Infectious agent Infection type Sample use Reference
QLA5 Domestic cat, SPF M. haemofelis Exptl Sequencing, serology Present study
1008 Domestic cat M. haemofelis Natural Sequencing 35
7415 Domestic cat M. haemofelis Natural Sequencing 35
Dalia Iberian lynx M. haemofelis Natural Sequencing 16
Cicuta Iberian lynx “Ca. Mycoplasma haemominutum” Natural Sequencingc 16
Y Domestic cat, SPF “Ca. Mycoplasma turicensis” Exptl Sequencing,b serology 18
09NFR2 Domestic cat, SPF “Ca. Mycoplasma haemominutum” Exptl Serology 7
Various (n  10) Domestic cat, SPF “Ca. Mycoplasma turicensis” Exptl Serology 18
Various (n  7) Domestic cat, SPF “Ca. Mycoplasma haemominutum” Exptl Serology 7
a The number of animals is indicated if it is more than one.
b The DnaK sequence of “Ca. Mycoplasma turicensis” could not be amplified.
c Only a partial DnaK sequence of “Ca. Mycoplasma haemominutum” could be amplified.
TABLE 2. Primers used for amplification and construction of the M. haemofelis DnaK and rDnaK genes
Primer namea Sequence (5–3) Length(bp)
Product
length (bp)
F1-35Mp GGCAAAAGAAATAATTTTAGGAATTGACTTAGG 33 976
R934-956Mhf CTTAACCAACTCCTGAACGGCAG 23
F600-623Var GTGGTGACGATTGGGATCAAGC 22 1,307
R1746-1768Ms CTGATGCAGCTTGTCCTCCAGCA 23
FDnaKMhfpET GCAGCACATATGGCAAAAGAAATAATTTTAGGAATTGACTTAGGb 44 1,824
RDnaKMhfpET GCAGCACTCGAGGGATTTAGTTTTATCTACCTCAGTCTTATCCTCc 45
F666-691Mhf GCACTTCAAAGACTTAAGGATGCCGC 26 1,119
R1750-1783Mhf TTAGGATTTAGTTTTATCTACCTCAGTCTTATCC 34
a Primer names indicate the forward (F) and reverse (R) orientation of the primers. All primers were used at a final concentration of 0.5 M each.
b Boldface indicates the NdeI recognition site.
c Boldface indicates the XhoI recognition site.
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(1,307 bp) for 30 s, 72°C for 60 s, and then a final elongation at 72°C for 10 min.
All DNA amplification steps of this study were performed using Phusion high-
fidelity DNA polymerase (Finnzymes, Espoo, Finland). The resulting PCR prod-
ucts of the expected lengths were extracted from agarose gels using the Nucle-
oSpin extract II kit (Macherey-Nagel, Du¨ren, Germany) according to the
manufacturer’s instructions. Gene sequences of the PCR products were deter-
mined by DNA sequencing (Microsynth, Balgach, Switzerland). Resulting M.
haemofelis DnaK gene and deduced protein sequences were compared to non-
redundant nucleotide and amino acid database sequences using the BLASTN
and BLASTP algorithms (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and were
aligned to the mycoplasma DnaK sequences of species shown in Fig. 1 using
ClustalW2 (11). The phylogenetic tree of mycoplasma DnaK protein sequences
was constructed using MEGA version 4 (27). Bootstrap support (1,000 repli-
cates) was calculated by the neighbor-joining method.
Gene construction and molecular cloning. The recombinant M. haemofelis
DnaK (M. haemofelis rDnaK) gene was obtained in two steps: first, the M.
haemofelis DnaK gene was amplified as two overlapping fragments from DNA
extracted from blood of cat QLA5 (using primer pairs F1-35Mp/R934-956Mhf
and F666-691Mhf/R1750-1783Mhf; Table 2). The resulting 976- and 1,119-bp-
long PCR products were extracted from agarose gels as described above and
assembled in a second step, which combined 10 ng of each of those fragments in
an overlap extension PCR (50-l reaction volume) using the overhang primers
FDnaKMhfpET and RDnaKMhfpET (Table 2). Those primers also inserted
NdeI and XhoI cleavage sites at the 5 and 3 ends of the gene, respectively. The
following cycling conditions were used: 5 cycles with an annealing temperature of
85°C, followed by the addition of primers, and 35 cycles with an annealing
temperature of 60°C (remaining cycling conditions were as described above).
The resulting PCR product (1,824 bp) was extracted from an agarose gel, di-
gested with restriction enzymes NdeI and XhoI (New England Biolabs, Ipswich,
MA) according to the manufacturer’s instructions, and ligated to the 4,690-bp
XhoI-NdeI fragment of vector pMG211 (24). The vector contained an ampicillin
resistance gene, a salicylate-inducible promoter, and the genetic information for
a C-terminal 6His tag followed by a stop codon. The correct M. haemofelis
rDnaK gene sequence within pMG211 was confirmed by DNA sequencing be-
fore protein production. For the DnaK complementation assay, the gene of E.
coli chorismate mutase (EcCM) (12, 25) was NdeI and XhoI digested and ligated
to the XhoI-NdeI fragment of plasmid pMG211 as described above.
Prokaryotic expression and purification of recombinant M. haemofelis DnaK.
Plasmid pMG211, containing the M. haemofelis rDnaK gene (naturally without
UGA readthroughs), was transformed into the recA-deficient Escherichia coli
strain XL1 blue (Stratagene, LaJolla, CA) for plasmid storage and multiplica-
tion. Cells were grown on LB agar containing 150 g/ml ampicillin and in LB
medium containing 200 g/ml ampicillin at 37°C and 250 rpm, respectively.
Plasmid DNA was purified using a Jetquick Plasmid Miniprep Spin kit
(Genomed, Lo¨hne, Germany). Transformed XL1 blue cells were stored as glyc-
erol stocks at 80°C. For protein production, plasmid pMG211 M. haemofelis
rDnaK was transformed into the kanamycin-resistant strain JW0013, an in-frame
DnaK knockout mutant of E. coli K-12 (2). Preparative cultures were inoculated
from overnight starter cultures and grown at 30°C and 250 rpm in LB medium
containing 150 g/ml ampicillin and 25 g/ml kanamycin. Gene overexpression
was induced with 1 mM salicylate at an optical density at 600 nm (OD600) of 0.6,
and the culture was incubated for an additional 20 h at 25°C and 250 rpm. After
cell lysis using 1 mg/ml lysozyme and ultrasonication, protein was purified from
the soluble fraction by affinity chromatography on Ni2-nitrilotriacetic acid
(NTA) agarose (Qiagen). The purification progress was assessed by SDS-PAGE
analysis (see below) after each purification step. Fractions containing monomeric
M. haemofelis rDnaK were isolated by size-exclusion chromatography on a cal-
ibrated Superdex 200 10/300 GL column (Amersham Pharmacia Biotech, Upp-
sala, Sweden) in Tris-buffered saline (TBS), pH 7.4. Those fractions then were
subjected to anion-exchange chromatography on a Mono Q HR 16/10 column
(Amersham Pharmacia Biotech) in TBS, pH 7.4, using a salt gradient from 150
to 500 mM NaCl. Fractions containing protein with a molecular mass of about 66
kDa were combined and concentrated using Amicon Ultra Centrifugal Filter 10
K (Millipore, Carrigtwohill, Cork, Ireland), and their protein concentration was
determined by the Bradford assay (Coomassie plus protein assay reagent cali-
brated with bovine serum albumin [BSA]; Thermo Scientific, Rockford, IL).
FIG. 1. Phylogenetic tree demonstrating the relationship of the deduced M. haemofelis DnaK protein sequences to mycoplasma DnaK protein
sequences from the GenBank database. Phylogenetic relationships were calculated using the neighbor-joining algorithm. Evolutionary distances
are shown to scale. The data set was resampled 1,000 times to generate bootstrap percentage values. Bootstrap values greater than 70% are given
at the nodes of the tree. GenBank accession numbers are indicated in parentheses. Mycoplasma groups, which previously have been classified based
on their 16S rRNA gene (23, 34) or on their RNase P RNA gene sequences (hemoplasma and haemofelis groups) (22), are indicated. The sequence
of E. coli served as an outgroup, establishing the root of the tree.
VOL. 17, 2010 RECOMBINANT ANTIGEN FOR STUDY OF HEMOPLASMA INFECTIONS 1919
Molecular mass determination of recombinant M. haemofelis DnaK. The mo-
lecular mass of M. haemofelis rDnaK protein was determined at the protein
service unit of the Functional Genomics Center Zurich (FGCZ), University of
Zurich, Zurich, Switzerland. The purified protein solution was analyzed using
electrospray ionization mass spectrometry. The experimentally determined mo-
lecular mass then was compared to the mass calculated by the ProtParam tool
(www.expasy.ch/tools/protparam.html) based on the deduced protein sequence
of M. haemofelis rDnaK.
Structure and stability determination. Circular dichroism (CD) spectroscopy
was performed on an Aviv circular dichroism spectrometer model 202 (Aviv
Instruments Inc., Lakewood, NJ) in quartz cuvettes of 0.2-cm path length (d).
Far-UV spectra were recorded from 260 to 200 nm in 1-nm steps at 25°C and a
1 M M. haemofelis rDnaK protein concentration (c) in TBS, pH 7.4 (50 mM
Tris base, 150 mM NaCl). For stability studies, KCl (100 mM) together with
MgCl2 (2.5 mM) and/or ATP (0.1 mM) were added. Data were collected for 5 s
at each step. Five scans were averaged, and buffer spectra determined under
identical conditions were subtracted. The observed ellipticity () at wavelength
 was transformed into molar ellipticity per residue (m,r) using equation 1
(where n is the number of residues), resulting in m,r  /(10  c  d  n).
Thermal denaturation experiments were performed in TBS, pH 7.4, at a 1 M
protein concentration by monitoring the CD signal at 222 nm from 10 to 95°C
and reverse in 0.5 K steps with 60 s of temperature equilibration, 60 s of data
collection, and a 1-K-per-min heating/cooling rate between temperature steps.
Tm, the melting point of the M. haemofelis rDnaK ATPase domain, was defined
as the inflection point of the melting curve and was determined from the first
derivative after curve smoothing using the SigmaPlot v11.0 software package
(Systat Software Inc., Richmond, CA).
ATPase activity assay. ATPase activity was measured using a spectrophoto-
metric assay (32), which quantified the released amount of inorganic phosphate
(Pi) during ATP hydrolysis. The reaction of 2-amino-6-mercapto-7-methyl-
purine-ribonucleoside (MESG) with Pi was catalyzed by the purine nucleoside
phosphorylase (PNP; Sigma-Aldrich, Buchs, Switzerland) and led to a measur-
able change in absorbance at 360 nm. MESG was synthesized and purified as
previously published (32). All measurements were performed at 25°C and 1 U/ml
PNP. The change in absorbance at 360 nm was calibrated to the Pi concentration
using MESG (190 M) and Pi (0, 1, 5, 25, and 50 M; from a 200 M Na2HPO4
solution). Michaelis-Menten kinetic measurements of M. haemofelis rDnaK then
where performed under the following ATPase assay conditions: 50 mM Tris, 100
mM KCl, 2.5 mM MgCl2, 400 nM purified M. haemofelis rDnaK, and 380 M
MESG. The change in absorbance at 360 nm was measured in duplicate for 26
min at ATP concentrations of 10, 50, 100, 250, and 500 M after an equilibration
time of 4 min in a Lambda 35 spectrophotometer (PerkinElmer, Waltham, MA).
Blank values measured without M. haemofelis rDnaK were subtracted, and the
reaction rates were calculated. The catalytic parameters kcat and Km were de-
termined from curve fitting to the Michaelis-Menten equation using the Sig-
maPlot v11.0 software package (Systat Software Inc.).
DnaK complementation assay. The E. coli DnaK knockout mutant strain
JW0013 was transformed with plasmid pMG211 containing either M. haemofelis
rDnaK or the EcCM gene (as a negative control). Liquid cultures were prepared
from both transformants and incubated at 30°C and 250 rpm overnight. Cell
densities of both cultures were adjusted to an OD600 of 3.0, and cultures then
were diluted sequentially 10-fold down to 106. One 5-l drop of each culture
and dilution was placed on LB agar plates containing 150 g/ml ampicillin, 25
g/ml kanamycin, and 1 mM salicylate. Agar plates were incubated without
ventilation at 30 or 43°C, respectively. Bacterial growth was assessed after 22.5 h
by counting colonies.
SDS-PAGE and recombinant antigen-based Western blotting. SDS-PAGE
and protein transfer to nitrocellulose membranes were performed in a Phast-
System high-speed electrophoresis system, a PhastSystem development unit, and
a PhastTransfer semidry electrophoretic blotting unit (all Amersham Pharmacia
Biotech). Recombinant M. haemofelis DnaK (540 ng/lane) was separated on
PhastGel 20% (wt/vol) homogenous SDS polyacrylamide gels (Amersham Phar-
macia Biotech), transferred, and Coomassie stained according to the manufac-
turer’s instructions. Western blots were probed with pre- and postinfection se-
rum or plasma samples from the experimentally infected cats QLA5 (M.
haemofelis; prior to and 21 dpi), 09NFR2 (“Ca. Mycoplasma haemominutum”;
prior to and 56 dpi), and Y (“Ca. Mycoplasma turicensis”; prior to and 109 dpi).
Serum and plasma samples were diluted 1:100 in blocking buffer (150 mM NaCl,
10 mM Tris base, 20 g/liter skimmed milk powder). Serum antibodies bound to
M. haemofelis rDnaK were visualized using peroxidase-conjugated, affinity-pu-
rified goat anti-cat IgG antibodies (diluted 1:2,000 in blocking buffer; Jackson
ImmunoResearch Laboratories, West Grove, PA) and 4-chloro-1-napthtol as the
chromogenic agent.
Recombinant antigen-based ELISA. M. haemofelis rDnaK was heated in coat-
ing buffer (100 mM Na2CO3, 0.1% [wt/vol] SDS, pH 9.6) to 100°C for 1 min and
then diluted 1:20 in coating buffer without SDS. Flat-bottomed 96-well microtiter
plates with medium binding capacity (Greiner Bio-One, Frickenhausen, Ger-
many) then were coated with 100 l of this M. haemofelis rDnaK solution per
well for 3 h at 37°C and overnight at 4°C. Plates subsequently were washed three
times with 200 l/well washing buffer (150 mM NaCl, 0.05% [vol/vol] Tween 20)
and incubated for 1 h at 37°C with 100 l/well blocking buffer (150 mM NaCl, 50
mM Tris base, 1 mM Titriplex III, 0.1% [wt/vol] BSA, 0.1% [vol/vol] Tween 20,
pH 7.4). After being washed as described above, 100 l of serum samples diluted
in serum buffer (blocking buffer without BSA) was added per well and incubated
for 1 h at 37°C. The plates were washed, and each well was filled with 100 l of
peroxidase-conjugated, affinity-purified goat anti-cat IgG antibodies (diluted
1:3,000 in serum buffer; Jackson ImmunoResearch Laboratories) and incubated
for 1 h at 37°C. After being washed, 100 l/well substrate solution [150 mM citric
acid pH 4.0, 1% (vol/vol) H2O2 2%, 1% (vol/vol) 2,2-azino-bis(3-ethylbenzo-
thiazoline-6-sulfonic acid) diammonium salt] was added, and plates were incu-
bated at room temperature for 10 min. Absorbance then was measured at a
wavelength of 415 nm (OD415) using a Spectramax Plus 348 microplate spectro-
photometer (Molecular Devices, Sunnyvale, CA).
Optimal serum dilutions and recombinant antigen concentrations were estab-
lished by a checkerboard titration using pre- and postinfection sera from the
three experimentally infected cats QLA5 (M. haemofelis; prior to and 21 dpi),
09NFR2C (“Ca. Mycoplasma haemominutum”; prior to and 56 dpi), and Y (“Ca.
Mycoplasma turicensis”; prior to and 109 dpi) at serum dilutions of 1:50, 1:100,
and 1:200. Antigen amounts of 200, 100, 50, and 10 ng/well were tested in
duplicate. Wells containing only antigen without serum served as blanks, and
wells containing preinfection serum samples served as negative controls.
Serum samples from 20 hemoplasma-free SPF cats before and after hemo-
plasma infection (Table 1) were tested using optimized conditions. For cat
QLA5, samples taken during the whole course of experimental M. haemofelis
infection (0 to 800 dpi) were assayed additionally. The signal-to-noise ratio was
determined by dividing the postinfection ELISA OD415 values by the corre-
sponding preinfection OD415 values.
Statistical analyses. Statistical analyses were performed using the SigmaPlot
v11.0 software package (Systat Software Inc.). Correlations between ELISA
antibody levels and M. haemofelis blood loads in the experimentally M. haemo-
felis-infected cat QLA5 were assessed using the Spearman rank-order correlation
test.
GenBank accession numbers. The nucleotide and deduced amino acid se-
quences of M. haemofelis DnaK have been deposited in the GenBank database
(HM594280, HM594281, and HM594283). Additionally, a partial “Ca. Myco-
plasma haemominutum” DnaK sequence, acquired using identical methods, was
submitted (HM594282).
RESULTS
M. haemofelis DnaK sequences. The obtained sequences of
the potential M. haemofelis DnaK gene included, according to
BLASTN search results, an open reading frame (ORF) most
similar to mycoplasma DnaK gene sequences (data not
shown). Compared to mycoplasma DnaK complete gene se-
quences from the GenBank database, the highest identities
with this ORF were found for M. suis DnaK (HspA1; 72%) and
Mycoplasma penetrans DnaK (69%). Identities with the two
partial M. haemofelis DnaK gene sequences FJ463263 (899 bp)
and AY150993 (303 bp) were 99 and 97%, respectively. Ac-
cordingly, the ORF was named the M. haemofelis DnaK gene.
Further comparisons of M. haemofelis DnaK gene sequences
derived from four different M. haemofelis-infected animals re-
sulted in three distinct M. haemofelis DnaK gene sequences:
from cats 7415 and QLA5 an identical sequence was obtained
(HM594280). Compared to the 7415/QLA5 sequence, se-
quences obtained from cat 1008 (HM594283) and lynx Dalia
(HM594281) shared the same 21 silent point mutations as well
as one point mutation causing a serine-to-glycine exchange at
position 580. The sequence from lynx Dalia (HM594281) ad-
ditionally contained a point mutation causing a proline-to-
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serine exchange at position 577. When the deduced M. hae-
mofelis DnaK protein sequence (cats 7415 and QLA5;
HM594280) was compared to mycoplasma DnaK sequences
from the GenBank database using the BLASTP search algo-
rithm, again M. suis (70%) and M. penetrans (65%) shared
highest identities. The phylogenetic analyses of the M. hae-
mofelis DnaK protein sequence revealed that it clustered
within the haemofelis group of the hemoplasmas, which is
distinct from other mycoplasma groups (Fig. 1).
Expression and biochemical characterization of the recom-
binant M. haemofelis DnaK. Ni-affinity chromatography of
crude extracts of salicylate-induced JW0013 pMG211 M. hae-
mofelis rDnaK cells yielded one predominant protein band
corresponding to a molecular mass of about 66 kDa (data not
shown). After size-exclusion chromatography, anion-exchange
chromatography, and protein concentration, M. haemofelis
rDnaK was judged to be pure by SDS-PAGE (Fig. 2A).
Mass spectrometry analysis determined the molecular mass
of M. haemofelis DnaK to be 66,406 Da, while the calculated
molecular mass based on its deduced protein sequence was
66,537 Da. This difference in mass of 131 Da corresponds to
the N-terminal loss of methionine during mass spectrometry
analysis.
CD spectrum analysis of M. haemofelis rDnaK showed two
distinct minima at 208 and 222 nm (Fig. 3A). The CD spectrum
of M. haemofelis rDnaK recorded without ATP or K and
Mg2 ions was not markedly different from those recorded
with additives. The temperature-dependent CD signals at 222
nm showed the thermally induced unfolding of M. haemofelis
rDnaK with well-defined (Tm1) and less-well-defined (Tm2)
temperature transitions (Fig. 3B). The melting temperature of
the nucleotide-binding domain of M. haemofelis rDnaK with-
out additives (Tm1a) was determined to be 42°C, the addition of
the nucleotide ATP increased it to a Tm1c of 46°C, and ATP
together with K and Mg2 ions further increased it to a Tm1d
of 50°C. The addition of K and Mg2 ions alone caused only
a minimal increase to a Tm1b of 43°C.
Enzymatic activity of the ATPase domain of M. haemofelis
rDnaK was determined in a spectrophotometric assay. Fitting
reaction rates at various substrate concentrations to the
Michaelis-Menten equation yielded catalytic parameters for
ATP hydrolysis (Fig. 3D).
During the DnaK complementation assay, the in vivo bio-
logical function of DnaKs, to allow bacterial growth at cell-
stressing temperatures by repairing damaged enzymes, was
tested for M. haemofelis rDnaK. No difference in the extent of
bacterial growth between M. haemofelis rDnaK and the EcCM
transformant could be seen for any of the tested culture dilu-
tions at 30°C (Fig. 3D). At 43°C, however, cells overexpressing
EcCM and lacking DnaK protein grew only until a dilution of
101 (20 colonies), while for rDnaK-expressing cells growth
until a 103 dilution (1 colony) was observed (Fig. 3D).
Immunogenicity of the recombinant M. haemofelis DnaK.
Western blot analyses of M. haemofelis rDnaK showed that the
protein was recognized by serum antibodies from cats experi-
mentally infected with M. haemofelis (cat QLA5), “Ca. Myco-
plasma haemominutum” (cat 09NFR2), and “Ca. Mycoplasma
turicensis” (cat Y). Preinfection serum or plasma samples from
the same cats did not result in a positive Western blot signal
(Fig. 2B).
For the M. haemofelis rDnaK ELISA, 50 ng M. haemofelis
rDnaK/well and a dilution of 1:200 for sera from M. haemofe-
lis-infected cats and 1:100 for sera from “Ca. Mycoplasma
haemominutum”- and “Ca. Mycoplasma turicensis”-infected
cats were found to be the optimal conditions. OD415 values for
serum samples from 20 SPF cats prior to hemoplasma infec-
tion ranged from 0.12 to 0.33 under these conditions. After
experimental infection, for the M. haemofelis-infected SPF cat
QLA5 the OD415 peaked at 1.4. For the eight “Ca. Myco-
plasma haemominutum”-infected SPF cats (Table 1), the
OD415 peak values ranged from 0.5 to 1.2, and for the 11 “Ca.
Mycoplasma turicensis”-infected SPF cats (Table 1), they were
between 0.7 and 1.5. The signal-to-noise ratio of the M. hae-
mofelis-, “Ca. Mycoplasma haemominutum”- and “Ca. Myco-
plasma turicensis”-infected SPF cats reached a maximum of
10.4, 10.4, and 10.6, respectively. A signal-to-noise ratio of at
least 1.5 was considered serologically positive for anti-M. hae-
mofelis rDnaK antibodies.
Experimental M. haemofelis infection and quantification of
anti M. haemofelis DnaK antibodies. The experimentally M.
FIG. 2. (A) SDS-PAGE of recombinant M. haemofelis DnaK for purity assessment after the final purification step of anion-exchange
chromatography. Lane M, low-molecular-weight marker (Amersham Pharmacia Biotech); lane 1, M. haemofelis rDnaK. (B) Western blot analyses
of samples from felines taken before and after hemoplasma infection using 540 ng recombinant M. haemofelis DnaK per lane. Blots were reacted
with serum from M. haemofelis-infected cat QLA5 preinfection (lane 2) and 21 dpi (lane 3), plasma from “Ca. Mycoplasma haemominutum”-
infected cat 09NFR2 preinfection (lane 4) and 56 dpi (lane 5), and serum from “Ca. Mycoplasma turicensis”-infected cat Y preinfection (lane 6)
and 109 dpi (lane 7). Lanes M, peqGold prestained protein marker IV (PEQLAB Biotechnologie; Erlangen, Germany).
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haemofelis-infected cat QLA5 turned M. haemofelis TaqMan
real-time PCR positive within 4 dpi and became anemic within
10 dpi (Fig. 4A). On the day of infection (0 dpi) the cat was
mildly anemic (hematocrit of 28%), probably due to a baseline
blood collection of 26 ml 11 days prior to M. haemofelis infec-
tion. However, the cat recovered to hematocrit values within
the reference range within a few days (7 to 9 dpi) before a
decrease in the hematocrit was observed starting at 10 dpi. The
minimum hematocrit value of 15% was measured 36 dpi (Fig.
4A). However, no severe clinical signs were observed that
necessitated blood transfusion or antibiotic treatment during
the course of infection, and the cat subsequently recovered
from anemia. From 148 dpi (5.3 months postinfection [mpi])
onwards, the hematocrit values stayed within the reference
range until the end of the experiment, 28.6 mpi (Fig. 4A and
data not shown).
The peak M. haemofelis load in blood (2.2  108 copies/ml
blood) was recorded at 29 dpi. Between 4 and 42 dpi the first
marked M. haemofelis copy number fluctuations were ob-
served; they ranged from 103 to 108 M. haemofelis copies/ml
blood within a minimum of 2 days (Fig. 4A). From 3.8 to 8.3
mpi a second episode of copy number cycling was observed; the
loads ranged from 102 to 105 copies/ml blood within a mini-
mum of 8 days. Five distinct M. haemofelis load peaks were
observed in 1- to 2-month intervals during this second cycling
period. QLA5 stayed PCR negative from 260 dpi (9.3 mpi)
until the end of the observation period at 28.6 mpi (Fig. 4A
and B).
The seroconversion of cat QLA5, defined as a signal-to-
noise ratio of at least 1.5, occurred between 8 (signal ratio, 1.3)
and 14 dpi (signal ratio, 6.9) (Fig. 4B). QLA5 stayed serolog-
ically positive until the end of the observation period at 28.6
MPI. Twelve and 18 mpi the signal-to-noise ratio dropped to a
minimum of 2.8, followed by a signal ratio increase to 6.0
without detectable amounts of M. haemofelis DNA in the cat’s
blood (Fig. 4B). The reinfection of QLA5 by its SPF compan-
FIG. 3. Biochemical and functional characterization of M. haemofelis rDnaK. (A) Circular dichroism spectra of M. haemofelis rDnaK in the
absence or presence of ATP and/or K and Mg2 ions. (B) Thermal denaturation curves of M. haemofelis rDnaK recorded at a wavelength of 222
nm in the absence or presence of ATP and/or K and Mg2 ions. T, temperature. (C) Michaelis-Menten plot of M. haemofelis rDnaK (400 nM)
showing ATPase activity at indicated ATP concentrations. The kinetic constants kcat and Km of M. haemofelis rDnaK were determined from curve
fitting to the Michaelis-Menten equation. (D) Evaluation of in vivo complementation of biological DnaK function by M. haemofelis rDnaK in the
DnaK-deficient E. coli strain JW0013 at permissive (30°C; upper) and nonpermissive (43°C; lower) temperatures. JW0013 cells were expressing
either the M. haemofelis rDnaK gene (M. haemofelis rDnaK) or the E. coli chorismate mutase gene (EcCM), the latter serving as a negative control.
Overnight cultures of transformed cells were diluted sequentially 10-fold down to 106 before being spotted onto selective agar plates supple-
mented with 1 mM salicylate. Their ability to grow was evaluated by counting colonies.
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ion cat was excluded as a cause for this ratio increase by
negative PCR and serology results for the companion cat be-
fore, during, and at the end of the observed infection period
(data not shown).
There was a significant positive correlation between the sig-
nal-to-noise ratio and M. haemofelis load when all pairs of
variants throughout the whole course of infection (n  32)
were included (Spearmen correlation coefficient, r  0.619;
P  0.0002) as well as when only pairs of variants from the
PCR-positive period (n  21; r  0.502; P  0.0202) were
included.
DISCUSSION
This is the first study to identify, characterize, and recombi-
nantly produce a full-length, highly pure antigen of feline he-
motropic mycoplasmas. The protein is an HSP70 protein and
belongs to the DnaK protein family. It is most closely related
to HspA1, the DnaK of M. suis (CAK22359); the latter protein
was demonstrated to be expressed on the surface of M. suis
cells and to have immunogenic potential (10). In analogy to
this, we found that hemoplasma-infected cats readily produced
antibodies to M. haemofelis rDnaK.
The protein cross-reacted with sera from cats experimentally
infected with M. haemofelis, “Ca. Mycoplasma haemominu-
tum” and “Ca. Mycoplasma turicensis,” but not with serum
samples from SPF cats. However, the optimization of the
ELISA resulted in higher sample dilutions for M. haemofelis
samples than for “Ca. Mycoplasma haemominutum” and “Ca.
Mycoplasma turicensis” samples, which indicates that the im-
munogenicity of M. haemofelis rDnaK is caused by conserved
as well as species-specific epitopes of this antigen. This would
be in agreement with the high identity (71%) that we found
between the M. haemofelis DnaK and the partial “Ca. Myco-
plasma haemominutum” DnaK gene sequence (1,304 bp;
HM594282) but also could explain why we were unable to
amplify the 3 end of the “Ca. Mycoplasma haemominutum”
DnaK gene sequence using consensus primers despite several
attempts (data not shown). The observed cross-reactivity is
also in agreement with a previous study using whole feline
hemoplasma antigen preparations (5). In the latter study, an-
tigen derived from H. felis large form (today known as M.
haemofelis) was tested with sera from cats infected with M.
haemofelis and “Ca. Mycoplasma haemominutum” (formerly
known as H. felis small form). M. haemofelis-derived whole
hemoplasma antigen cross-reacted with sera from M. haemo-
felis and “Ca. Mycoplasma haemominutum”-infected cats,
while “Ca. Mycoplasma haemominutum”-derived antigen was
recognized only by sera from “Ca. Mycoplasma haemominu-
tum”-infected cats.
The antigen M. haemofelis rDnaK was purified to homoge-
neity from potentially antigenic proteins originating from the
production process to improve the signal quality of the sero-
logical assays and to minimize interbatch variations in antigen
quality. Indeed, M. haemofelis rDnaK protein expression and
purification was repeated with identical results. The identity of
the protein was proven by the comparison of the observed and
calculated molecular masses of M. haemofelis rDnaK. CD spec-
trum analysis of M. haemofelis rDnaK revealed two minima (at
208 and 222 nm), suggesting that it consisted mostly of 	-he-
lices (8), which is in good agreement with known DnaK struc-
tures, e.g., of E. coli (Protein Database identiy [PDB ID]:
2KH0) and G. kaustophilus (PDB ID: 2V7Y). The structure
profile of M. haemofelis rDnaK was insensitive to a change in
the presence of nucleotide, as has been shown before for Ba-
cillus licheniformis DnaK (13), and also in the presence of K
and Mg2 ions. The thermal denaturation of M. haemofelis
rDnaK was characterized by two temperature transitions. This
corresponded well to an earlier study (17), where deletion
mutants of E. coli DnaK were used. The authors demonstrated
that the first transition (Tm1) was related to the unfolding of
the DnaK N-terminal nucleotide-binding domain, while the
second transition was related to the unfolding of the C-termi-
nal substrate-binding domain. A raising of Tm1 in the presence
of nucleotide, as also observed for M. haemofelis rDnaK, was
reported for E. coli DnaK to be caused by a stabilizing effect
occurring due to the ligand binding to the nucleotide-binding
domain of the protein (20). As found for M. haemofelis rDnaK,
FIG. 4. Course of experimental M. haemofelis infection in cat
QLA5: hematocrit, M. haemofelis load, and anti-M. haemofelis rDnaK
antibodies. (A) Hematocrit and M. haemofelis blood copy numbers
during the first year of experimental M. haemofelis infection. M. hae-
mofelis blood copy numbers were determined using TaqMan real-time
PCR (35). The dashed lines indicate the lower and the upper limit (5
and 95% quantiles) of the hematocrit reference range (33 to 45%).
(B) Anti-M. haemofelis rDnaK serum antibodies and M. haemofelis
blood copy numbers during 29 months of experimental M. haemofelis
infection.
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this stability was supposed to be further enhanced in the pres-
ence of nucleotide together with K and Mg2 ions, which
mediate contacts between DnaK and nucleotide (15, 33). The
kinetic constants for ATP hydrolysis by pure M. haemofelis
rDnaK (kcat  0.015/min; Km  23 M; kcat/Km  650/M/min)
(Fig. 3C) were comparable to those published for E. coli
DnaK, which showed kcat values ranging from 0.02 to 0.2/min
(3) and Km values ranging from 20 nM to 20 M (4, 14). This
indicated that M. haemofelis rDnaK possesses a typically low
ATPase activity when evaluated without its cochaperones
DnaJ and grPE. The DnaK complementation assay confirmed
the molecular chaperone activity of M. haemofelis rDnaK in an
E. coli DnaK knockout mutant at heat shock temperatures.
This heat shock protein activity serves as another piece of true
evidence for the identity of M. haemofelis DnaK.
We demonstrated for the first time that an experimentally
M. haemofelis-infected cat mounted antibodies to M. haemo-
felis rDnaK within 8 to 14 days after experimental infection and
shortly after the cat’s blood was M. haemofelis PCR positive.
Moreover, we found a correlation between the M. haemofelis
blood loads and antibody levels. This indicates that M. hae-
mofelis DnaK is immunogenic and that the recombinant anti-
gen is suited for use in quantitative serological assays and to
demonstrate seroconversion in infected animals.
The experimentally M. haemofelis-infected cat stayed sero-
logically positive for more than 2 years postinfection and for
more than 1.5 years after turning PCR negative for M. hae-
mofelis in the blood. So far, we have data from only one M.
haemofelis-infected cat. However, earlier results from “Ca. My-
coplasma turicensis” infection (18) and preliminary follow-up
data from these cats (M. Novacco, G. Wolf-Ja¨ckel, H. Lutz,
and R. Hofmann-Lehmann, unpublished data) confirm the
persistence of anti-M. haemofelis rDnaK antibodies in the ab-
sence of PCR positivity in blood. This indicates that there is
active antigen stimulation in the chronic phase of hemoplasma
infection, possibly by antigen sequestered in the tissue. We
have postulated that the decline of Western blot signal in two
cats after the antibiotic treatment of experimental “Ca. Myco-
plasma turicensis” infection could have been due to therapy-
induced “Ca. Mycoplasma turicensis” clearance from blood
and tissues (18), whereas “Ca. Mycoplasma turicensis” antigen
sequestered in the tissues of 10 untreated cats could have
resulted in the continuous low-level stimulation of the humoral
immune system (18). The latter would be in agreement with
the findings from two experimentally “Ca. Mycoplasma turi-
censis”-infected cats: in nearly all tissues collected from those
two cats at 20 and 94 dpi, more “Ca. Mycoplasma turicensis”
copies were found than expected to result from blood contam-
ination alone, which suggested that “Ca. Mycoplasma turicen-
sis” can become concentrated in organs of infected cats (S.
Tasker, personal communication). However, for M. haemofelis
no evidence for significant tissue sequestration has been found
so far (30).
In conclusion, this study provides evidence that M. haemo-
felis rDnaK, the antigen we have identified, recombinantly
produced, and characterized herein, has biochemical and mo-
lecular chaperone properties of the HSP70/DnaK family. It has
been applied successfully to quantify anti-feline hemoplasma
antibodies in samples from experimentally infected cats, as
well as to monitor seroconversion after experimental infection
when used in Western blot assays and ELISA. The antigen and
the assays are prerequisites to gain more insight into the course
of hemoplasma infections, e.g., by investigating hemoplasma
pathogenesis in experimental infection setups. In addition, the
described antigen may have the potential to be used in a rapid
test for clinicians, supporting quick diagnosis and faster choice
of adequate therapy of feline hemolytic anemia. However,
further studies will be necessary to fully evaluate the cross-
reactivity of this antigen with antibodies directed against other
bacterial pathogens and its potential benefit for testing samples
from naturally hemoplasma-infected cats.
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